ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.

Saved in:
Bibliographic Details
Main Authors SZILLAT, Hauke, HEINELT, Uwe, RACKELMANN, Nils, MENDEZ-PEREZ, Maria, RITTER, Kurt, DEFOSSA, Elisabeth, ZECH, Gernot, MATTER, Hans
Format Patent
LanguageEnglish
French
German
Published 18.09.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
Bibliography:Application Number: EP20220817150